Ataxia Global Market Report 2024

The ataxia market size has grown strongly in recent years. It will grow from $33.78 billion in 2023 to $37.01 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historic period can be ascribed to factors such as the limited availability of treatment options, advancements in neurological research, heightened awareness of rare diseases, ongoing evolution of diagnostic technologies, and an increased focus on understanding genetic factors.

The ataxia market size is expected to see strong growth in the next few years. It will grow to $51.3 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be attributed to the accelerated development of drugs for ataxia, increased investments in rare disease research, the adoption of precision medicine approaches, a heightened focus on patient advocacy, and a growing understanding of the genetic basis of ataxia. Major trends expected in the forecast period include the integration of digital health solutions in ataxia management, the development of gene therapies for ataxia treatment, a rise in collaborative research initiatives, an emphasis on patient-centric care models, and the adoption of telemedicine for ataxia consultations.

The escalation in alcohol consumption is poised to be a significant driver behind the expansion of the ataxia market in the foreseeable future. Chronic alcohol misuse, a leading cause of acquired toxic ataxia termed cerebellar degeneration, contributes to prevalent ataxic conditions. Individuals with alcoholism often exhibit symptoms such as lower limb postural tremors and gait ataxia. For example, data from the Global Beer Consumption Report for 2021, disclosed by Kirin Holdings Company Limited in December 2022, indicated a substantial increase in worldwide beer consumption, totaling about 185.60 million kiloliters in 2021 - a 4.0% rise from the preceding year. This surge, partly influenced by the post-COVID-19 scenario, marked an elevation of roughly 7.13 million kiloliters, driving the total beer consumption to approximately 185.6 million kiloliters. Consequently, the heightened alcohol consumption serves as a catalyst propelling growth within the ataxia market.

The upsurge in healthcare expenditure is anticipated to drive the expansion of the ataxia market in the coming years. Elevated healthcare spending encompasses the allocation of resources toward advanced research, development, and accessibility of innovative treatments and therapies targeting ataxia-related conditions. As healthcare expenditures rise, there's a concerted effort to enhance the understanding and management of ataxia. For instance, projections from the 2021–2030 National Health Expenditure (NHE) report, released by the Centers for Medicare & Medicaid Services in March 2022, indicated an average annual increase of 5.1% in national health spending, foreseeing a substantial rise to approximately $6.8 trillion by 2030. Consequently, the upward trajectory in healthcare expenditure acts as a driving force behind the growth observed within the ataxia market.

Innovative product development is a prominent trend gaining momentum within the ataxia market. Leading companies within this domain are committed to introducing novel products or drugs to fortify their market presence. A case in point is the announcement made by Reata Pharmaceuticals in February 2023, unveiling the FDA approval of SKYCLARYS (omavaloxolone). This groundbreaking medication stands as the inaugural drug indicated specifically for individuals with Friedreich's ataxia, encompassing adults and adolescents aged 16 and above. Notably, treatment with SKYCLARYS demonstrated a statistically significant reduction in mFARS (modified Friedreich's Ataxia Rating Scale) scores at Week 48, evidencing diminished impairment compared to a placebo. Friedreich's ataxia, an exceedingly rare inherited neurological disorder, is commonly diagnosed during adolescence.

Strategic partnerships have emerged as another pivotal trend within the ataxia market, as major players focus on forging alliances to bolster their market positioning. An illustrative example is the collaboration between CRISPR Therapeutics, a Switzerland-based biopharmaceutical company, and Capsida Biotherapeutics Inc., a US-based biotechnology company, announced in June 2021. This collaboration is centered on researching, developing, manufacturing, and commercializing novel gene editing therapies targeting Friedreich's ataxia and familial amyotrophic lateral sclerosis (ALS). Under this agreement, CRISPR Therapeutics leads the research and development efforts for the Friedreich's ataxia program, overseeing gene-editing activities for both programs. Capsida, on the other hand, spearheads the research and development initiatives for the ALS program, focusing on capsid engineering for both therapeutic programs.

In December 2022, Solid Biosciences Inc., a US-based biotech company, successfully completed the acquisition of AavantiBio Inc. for an undisclosed amount. This strategic move allows Solid Biosciences Inc. to gain access to AavantiBio's portfolio of neuromuscular and cardiac programs. Notable assets acquired include the differentiated gene transfer candidate SGT-003 for Duchenne, the gene transfer candidate AVB-202 for Friedreich's ataxia, the gene transfer candidate AVB-401 for BAG3-mediated dilated cardiomyopathy, along with additional assets designed for the treatment of unspecified cardiac diseases. AavantiBio Inc. is recognized as a leading gene therapy company in the United States, specializing in the treatment of Friedreich's ataxia and cardiovascular diseases.

Major companies operating in the ataxia market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Viatris Inc., Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Celgene Corporation, Vertex Pharmaceuticals Incorporated, Banner Health, UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Genentech Inc., Ipsen Biopharmaceuticals Inc., Aurobindo Pharma Limited, Apotex Inc., Amneal Pharmaceuticals LLC, Biogen Inc., Lupin Limited.

North America was the largest region in the ataxia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the ataxia market report during the forecast period. The regions covered in the ataxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ataxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of ataxias encompass Friedreich's ataxia, ataxia-telangiectasia, episodic ataxia, and others. Friedreich's ataxia is a rare genetic disorder that disrupts movement and progressively damages the nervous system. Treatment options and diagnostic methods are available for managing this condition. These treatments come in different forms, including solids and liquids, and can be administered through various routes such as oral and parenteral. The end-users for these treatments include hospitals, clinics, home healthcare, and others.

The ataxia market research report is one of a series of new reports that provides ataxia market statistics, including ataxia industry global market size, regional shares, competitors with a ataxia market share, detailed ataxia market segments, market trends and opportunities, and any further data you may need to thrive in the ataxia industry. This ataxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ataxia market consists of revenues earned by entities by providing serotonergic therapy, occupational therapy, vestibular rehabilitation, and hyperbaric oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ataxia market also includes sales of adaptive devices including walkers or canes, acetazolamide, and amantadine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.